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Abstract Primary small cell carcinoma (SSC) of the liver
is very rare in Japan and only ten cases have been reported
worldwide. We report herein the case of a 77-year-old man
withprimarySCCoftheliver.Hehadatumorover10 cmin
diameterwhichwaslocalizedintherightlobeoftheliverand
had invaded the right diaphragm. In laboratory tests, high
serum levels of lactate dehydrase and neuron-speciﬁc eno-
lase were observed. A biopsy specimen showed that the
tumor cells were similar in cytology to a pulmonary SCC.
The patient was ﬁrst treated with carboplatin and etoposide
according to the therapy protocol for pulmonary SCC and
then with a regimen using etoposid and cisplatinum, result-
ing in an unfavorable outcome. We discuss the clinical
course and therapy of extra-pulmonary SCC and review the
literature of the cases previously reported.
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Introduction
Small cell carcinoma (SCC) is relatively common and
accounts for about 20% of lung cancer. Chemotherapy, not
resection or radiation, is the sole therapy for SCC of the
lung, indicating a poor prognosis. Although the majority of
SCC are located in lungs, the minority (2.5–4.1%) has been
reported to be from extrapulmonary organs, including
esophagus, thymus, stomach, pancreas, and cervix.
Accordingly, these are diagnosed as extrapulmonary SCC
(EPSCC). Almost the half of the EPSCC are localized in
the gastrointestinal tract. The occurrence of EPSCC in
other organs is considered to be rare [1–3]. Chemotherapy
is the sole treatment for EPSCC and the regimens usually
are similar to those for lung SCC. They include the com-
bination of either etoposide and cisplatinum, or
camptothecin and cisplatinum [4, 5].
Primary liver cancers in Japan comprise 94.5% hepa-
tocellular carcinoma (HCC) and 3.6% cholangiocellular
carcinoma [6]. While no case of EPSCC originating from
the liver has been reported from Japan, only ten cases of
primary SCC of the liver have been reported worldwide
[7–11]. Here, we report a case of primary SCC of the liver
that was treated with carboplatin and etoposide.
Case report
A 77-year-old man was admitted to the Department
of Hepatology, Osaka City University Hospital, with a
3-month history of general fatigue, breathlessness, and a
high serum lactate dehydrase level. Physical examination
revealed a slight tenderness at the right costal region.
Abdominal magnetic resonance imaging (MRI) indicated
a hepatic mass of 10 cm in diameter in the right lobe of
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DOI 10.1007/s12072-008-9090-1the liver (Fig. 1a) that also showed invasion of the right
diaphragm in gallium scintigraphy (Fig. 1b). The results
of laboratory tests are shown in Table 1. In addition to
the increase in aspartate transaminase (64 IU/l), alanine
aminotransferase (390 U/l), and lactate dehydrase
(6,480 IU/l), neuron-speciﬁc enolase (NSE) increased to
389 U/ml (normal range, 0–10 U/ml). Alpha-fetoprotein
increased slightly to 27 ng/dl (normal range 0–20 ng/ml).
Hepatitis B surface antigen (HBsAg) and antibodies to
hepatitis C virus (anti-HCV) were negative. Antinuclear
antibodies and antimitochondrial antibodies were all
negative. Nine years earlier, the patient was diagnosed
with prostate cancer and was treated with radiation ther-
apy and chemotherapy. He was a nonsmoker and not
obese (body mass index, 25.0 kg/m
2).
We performed a target needle biopsy of this liver tumor.
The microscopic view of the biopsy specimen stained with
hematoxylin and eosin indicated a pathologically small,
round cell carcinoma (Fig. 2). Immunohistochemical
staining revealed that cytokeratin (multi) (AE1/AE3) and
cytokeratin CAM5.2, which represents cytokeratin 1–8/10/
14/15/16/19, were positive. However, Ki-1, NSE, desmin,
and vimentin were negative (Fig. 3). No components of
leukemia, HCC, or adenocarcinoma were present.
Chest radiographic examination, chest computed tomo-
graphic scan, endoscopy of both the stomach and the colon,
and ﬂuorodeoxyglucose positron emission tomography
(FDG-PET) were performed to exclude the possibility of
metastatic tumor from the lung or other extrahepatic
organs. Accumulated absorption of ﬂuorodeoxyglucose
was observed in abdominal lymph nodes, as well as in the
liver tumors, by the FDG-PET. However, no malignant
lesions were detected elsewhere in the body (Fig. 1c).
Accordingly, we diagnosed this case as an inoperable pri-
mary liver SCC.
We started platinum-based chemotherapy with carbo-
platin AUC 5 on the ﬁrst day and etoposide (VP-16)
120 mg/m
2 on days 1–3 per month. We followed up and
assessed the effect of the chemotherapy by MRI and FDG-
PET. The assessment was carried out using the criteria of
Fig. 1 Image analyses of the liver tumor. (a) MRI indicates a 10-cm-
sized liver mass with extrahepatic growth in S5/8. (b) Gallium
scintigraphy shows the huge mass in the liver (arrows) and its
invasion of the right diaphragm (arrowheads). (c) In FDG-PET,
accumulated absorption is observed in the liver mass, abdominal
lymph nodes (arrow), and the invading tumor in the right diaphragm
(arrowheads)
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123World Health Organization and was indicated as a stable
disease. During the therapy, we used granulocyte colony-
stimulating factor (150 lg/day) for a total of 6 days against
the major adverse effects of neutropenia (grade 4, National
Cancer Institute—Common Toxicity Criteria). Next, we
treated the patient with the second-line chemotherapy
regimen using 40 mg of cisplatinum on days 1–3/month
instead of carboplatin. Unfortunately, assessment showed
progression of the disease. The performance status (PS)
became PS3 using the criteria of the Eastern Cooperative
Oncology Group after the second-line therapy and we
selected a best supportive care approach according to the
patient’s wishes. He died about 3 months after admission
in our hospital.
Discussion
EPSCC is a very rare malignant tumor and accounts for
about 5% of all SCC. Duguid and Kennedy [12] ﬁrst
described two cases of mediastinal oat cell tumor in 1930.
Since then, EPSCC has been recognized increasingly as a
distinct clinical entity and has been reported in several
organs other than the lung over the past 30 years. Primary
locations include the head, neck, salivary glands, thyroid,
larynx, trachea, thymus, pleura, esophagus, stomach,
intestines, rectum, pancreas, gall bladder, cervix, uterus,
breast, prostate, urinary bladder, and skin [1–3].
In general, the clinical course of EPSCC is progres-
sive in nature and the tumor often recurs after treatment.
Kim et al. [2] analyzed 34 cases, and the median sur-
vival of EPSCC in their study was 14 months. In their
study, the overall survival of the patients with limited
disease was more favorable than those of with extensive
disease. EPSCC as a gastrointestinal tumor was espe-
cially unfavorable. More than 50% of patients with
limited disease were operated upon or received radio-
therapy in combination with chemotherapy for local
control, it resulting in differing survival between limited
disease and extensive disease [2]. Primary SCC of the
liver is very rare and only ten cases have been described
in the literature until now (Table 2). In the three cases
reported by Zanconati et al. [7], one patient was treated
by mass resection but the others received no therapy.
The clinical progression was rapid and death ensued
between 1 and 5 months after diagnosis. In the two cases
reported by Sengoz et al. [8], one patient who received
chemotherapy survived for 13 months and the other
survived for 67 months after hemihepatectomy. In a case
reported by Kim et al. [9], in which segmentectomy of
the liver and adjuvant chemotherapy were performed, the
patient survived with no signs of recurrence for at least
Fig. 2 Hematoxylin and eosin staining of the needle biopsy speci-
men. Microscopic ﬁndings of the tumor reveal the accumulation of
small round cells that are similar to SCC of the lung and the presence
of cell necrosis (*). The tumor cells show oval to fusiform
hyperchromatic nuclei and indistinct nucleoli with frequent mitoses
(arrows). Magniﬁcation, 4009
Table 1 The results of
laboratory tests
WBC 3,100/ll BUN 15 mg/dl HBsAg (-)
RBC 399 9 10
4/ll Cre 0.77 mg/dl Anti-HCV (-)
Hb 12.1 g/dl UA 7.2 mg/dl CEA 1.8 ng/ml
Hct 35.5% Na 136 mEq/l CA 19–9 33 U/ml
PLT 17.6 9 10
4/ll K 3.9 mEq/l AFP 27 ng/ml
AST 64 IU/l Cl 94 mEq/l PIVKA-II 16 mAU/ml
ALT 390 IU/l FBS 89 mg/dl NSE 389 U/ml
ALP 390 IU/l T-cho 174 mg/dl PSA 0.418 ng/mL
c-GTP 447 IU/l TG 117 mg/dl LD 6,480 IU/l
LAP 159 IU/l CRP 2.00 mg/dl LDH-1 25.2%
ChE 225 IU/l PT 98% LDH-2 39.0%
T-Bil 0.8 mg/dl APTT 31.2 s LDH-3 24.0%
TP 6.8 g/dl HPT 75% LDH-4 8.8%
ALB 3.8 g/dl LDH-5 3.0%
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1234 months. In another two reported cases, the patients
received continued treatment with combined chemother-
apy and survived [10, 11]. The aforementioned cases of
primary SCC of the liver, in which radical operation or
combined chemotherapy was performed, had a good
prognosis.
The regimens of chemotherapy were similar between
lung SCC and EPSCC and consisted of platinum-based
combination therapy. In our case, the tumor was diag-
nosed as an extensive disease because it had invaded the
right diaphragm and metastasis to the abdominal lymph
nodes was also identiﬁed. Accordingly, this tumor was
found to be inoperable. Furthermore, on MRI and FDG-
PET, it showed no response to the cisplatin-based che-
motherapy, although the serum level of NSE decreased
from 389 U/ml to 37 U/ml after the ﬁrst chemotherapy
session.
SCC of the liver was found to express c-kit, a stem cell
marker of the liver, in Choi’s report [10]. Recently, it has
been considered that EPSCC may arise from a multipo-
tential stem cell that is capable of differentiating into SCC.
Our and Zanconati’s cases were positive for AE1/AE3,
being compatible with a carcinoma derived from biliary
epithelium, rather than of neuroendocrine origin.
Fig. 3 Immunohistochemical staining of the tumor tissue. The tumor
cells are positive for AE1/AE3 (a) and CAM5.2 (b), but are negative
for Ki-1 (c), desmin (d), NSE (e), and vimentin (f). Magniﬁcation,
1009. AE1/AE3 and CAM5.2 are representative epithelial cell
markers. Desmin and vimentin are nonepithelial and mesenchymal
cell markers. Ki-1 is a marker for lymphoma. NSE is a marker of
neuroendocrine origin
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Table 2 Patients with primary SCC of the liver
Author Age Sex Stage of
disease
Size
(cm)
Positive
immunohistochemical
staining
Negative
immunohistochemical
staining
Treatment Status/
survival
(months)
Ryu et al. 55 M Extensive 8 CD56, c-kit, (±) SYN TTF-1 Chemotherapy Alive
Kim et al. 53 M Extensive 12 CD56, NSE, c-kit, SYN,
mixed CK, EMA
CK7, 8, 19, 20, AFP, CEA,
hepatocyte, vimentin,
desmin, TTF-1
Segmentectomy,
adjuvant chemotherapy
(cisplatin, etoposide)
Alive
Zanconati et al. 56 M Limited 5 AE1/AE3, CK8, 18, 19,
NSE, AFP
S-100 protein, CEA No Dead/1
Zanconati et al. 69 M Extensive 10 AE1/AE3, CK8, 18, 19,
(±) NSE, CHR
S-100 protein, CEA No Dead/1
Zanconati et al. 89 M Extensive 6 AE1/AE3, CK8, 18, 19,
AFP, NSE
CHR, S-100 protein, CEA No Dead/1
Kim et al. 67 M 12 SYN, CD56, c-kit CK, CEA, AFP Chemotherapy
(cisplatin, epirubicin)
Alive
Sengoz et al. 73 F Right hemihepatectomy Dead/67
Sengoz et al. 66 M Chemotherapy (cisplatin) Dead/13
Kim et al. CHR, SYN
Choi et al. 82 F Extensive 6.7 CD56, NSE, SYN, CHR,
TTF-1, c-kit
Antihepatocyte, AFP,
vimetin, desmin, CK7, 19,
20, CEA, S-100 protein
Segmentectomy,
chemotherapy
(etoposide)
Alive
This case 77 M Extensive 10 AE1/AE5, CAM5.2 NSE, desmin, vimentin Chemotherapy
(cisplatin, etoposide)
Dead/3
AFP, alpha-fetoprotein; CEA, carcinoembryonic antigen; CHR, chromogranin; CK, cytokeratin; EMA, epithelial membrane antigen; NSE,
neuron-speciﬁc enolase; SYN, synaptophysin; TTF-1, thyroid transcription factor 1
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